Thomas M. Barnes

Tom is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations for over 20 years and has co-founded or helped launch several companies, including Intellia Therapeutics and Eleven Biotherapeutics. While at Intellia Therapeutics, a CRISPR/Cas9 company which Tom joined as Chief Scientific Officer, he helped build the research team, raise funds (including an IPO), and provide a vision for technology extension. He played a significant role as the corporate spokesperson to lay and industry press, and to governmental and non-governmental organizations on the rapidly evolving and intensely followed CRISPR landscape. Tom has wide-ranging knowledge of biological systems through his work across diverse platforms including gene editing, genomics and gene discovery, small molecule drug repositioning, and protein engineering. He received his PhD from the University of Cambridge and completed research fellowships at Harvard Medical School and McGill University. He is currently also an Executive Partner at MPM.